In 1698 adults with type 2 diabetes on metformin, oral orforglipron 12 mg and 36 mg was non-inferior and superior to oral semaglutide 7 mg and 14 mg for HbA1c change at 52 weeks (36 mg vs 14 mg: −0.44%), with more GI events and discontinuations.
RCTn = 1,698
Rosenstock et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial